Current Pain and Headache Reports

, Volume 8, Issue 3, pp 229–237 | Cite as

Menstrual migraine: A review of prophylactic therapies

  • Vincent T. Martin


Menstrual migraine is commonly encountered in women who are experiencing attacks of migraine without aura. It remains controversial whether attacks of menstrually associated migraine are more severe and have a longer duration than non-menstrually associated attacks. The pathogenesis of menstrual migraine is not understood completely, but it may be related to estrogen withdrawal or prostaglandin release. Preventative therapies may be considered in those who have failed abortive medications or have attacks lasting longer than 2 days. They can be administered short-term during the perimenstrual time period or continuously throughout the menstrual cycle. Short-term prophylactics should be tried first because menstrual migraines generally last for 1 to 4 days only. Continuous prophylactics may be considered in those with attacks refractory to short-term therapies.


Migraine Sumatriptan Naproxen Sodium Migraine Headache Migraine With Aura 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Silberstein SD, Merriam GR: Estrogens, progestins, and headache. Neurology 1991, 41:786–793.PubMedGoogle Scholar
  2. 2.
    Nattero G: Menstrual headache.In Advances in Neurology. Edited by Critchley M. New York: Raven Press; 1982:215–226.Google Scholar
  3. 3.
    Silberstein S, Merriam G: Sex hormones and headache (menstrual migraine). Neurology 1999, 53(suppl 1):S3-S13. Important review of the female reproductive cycle and the pathophysiology of menstrual migraine.PubMedGoogle Scholar
  4. 4.
    MacGregor EA: Menstruation, sex hormones, and migraine. Neurol Clin 1997, 15:125–141. Gives an excellent synopsis of the pathophysiology of menstrual migraine.PubMedCrossRefGoogle Scholar
  5. 5.
    Somerville BW: The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 1972, 22:355–365.PubMedGoogle Scholar
  6. 6.
    Somerville BW: The role of progesterone in menstrual migraine. Neurology 1971, 21:853–859.PubMedGoogle Scholar
  7. 7.
    Lichten EM, Lichten JB, Whitty A, et al.: The confirmation of a biochemical marker for women’s hormonal migraine: the depo-estradiol challenge test. Headache 1996, 36:367–371.PubMedCrossRefGoogle Scholar
  8. 8.
    Li W, Zheng T, Altura BM, et al.: Sex steroid hormones exert biphasic effects on cytosolic magnesium ions in cerebral vascular smooth muscle cells: possible relationships to migraine frequency in premenstrual syndromes and stroke incidence. Brain Res Bull 2001, 54:83–89.PubMedCrossRefGoogle Scholar
  9. 9.
    Benedetto C, Allais G, Ciochetto D, et al.: Pathophysiological aspects of menstrual migraine. Cephalalgia 1997, 17(suppl 20):32–34.PubMedGoogle Scholar
  10. 10.
    Nattero G, Allais G, De Lorenzo C, et al.: Relevance of prostaglandins in true menstrual migraine. Headache 1989, 29:233–238.PubMedCrossRefGoogle Scholar
  11. 11.
    Carlson LA, Ekelund LG, Oro L: Clinical and metabolic effects of different doses of prostaglandin E1 in man: prostaglandin and related factors. Acta Med Scand 1968, 183:423–430.PubMedCrossRefGoogle Scholar
  12. 12.
    Irwin J, Morse E, Riddick D: Dysmenorrhea induced by autologous transfusion. Obstet Gynecol 1981, 58:286–290.PubMedGoogle Scholar
  13. 13.
    MacGregor EA, Chia H, Vohrah RC, et al.: Migraine and menstruation: a pilot study. Cephalalgia 1990, 10:305–310. The original article that makes recommendations on the definition of menstrual migraine.PubMedCrossRefGoogle Scholar
  14. 14.
    International Headache Society Subcommittee: The international classification of headache disorders. Cephalalgia 2004, 24(suppl 1):139.Google Scholar
  15. 15.
    Dzoljic E, Sipetic S, Vlajinac H, et al.: Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache 2002, 42:185–193.PubMedCrossRefGoogle Scholar
  16. 16.
    Granella F, Sances G, Zanferrari C, et al.: Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 1993, 33:385–389.PubMedCrossRefGoogle Scholar
  17. 17.
    Granella F, Sances G, Pucci E, et al.: Migraine with aura and reproductive life events: a case control study. Cephalalgia 2000, 20:701–707.PubMedCrossRefGoogle Scholar
  18. 18.
    Cupini LM, Matteis M, Troisi E, et al.: Sex-hormone-related events in migrainous females: a clinical comparative study between migraine with aura and migraine without aura. Cephalalgia 1995, 15:140–144.PubMedCrossRefGoogle Scholar
  19. 19.
    Mattsson P: Hormonal factors in migraine: a populationbased study of women aged 40 to 74 years. Headache 2003, 43:27–35.PubMedCrossRefGoogle Scholar
  20. 20.
    Koseoglu E, Nacar M, Talaslioglu A, et al.: Epidemiological and clinical characteristics of migraine and tension-type headache in 1146 females in Kayseri, Turkey. Cephalalgia 2003, 23:381–388.PubMedCrossRefGoogle Scholar
  21. 21.
    Johannes CB, Linet MS, Stewart WF, et al.: Relationship of headache to phase of the menstrual cycle among young women: a daily diary study. Neurology 1995, 45:1076–1082.PubMedGoogle Scholar
  22. 22.
    Couturier EG, Bomhof MA, Neven AK, et al.: Menstrual migraine in a representative Dutch population sample: prevalence, disability, and treatment. Cephalalgia 2003, 23:302–308.PubMedCrossRefGoogle Scholar
  23. 23.
    Stewart WF, Lipton RB, Chee E, et al.: Menstrual cycle and headache in a population sample of migraineurs. Neurology 2000, 55:1517–1523. A population-based epidemiological study describing the relationship of migraine attacks to the female menstrual cycle.PubMedGoogle Scholar
  24. 24.
    Granella F, Sances G, Allais G, et al.: Characteristics of menstrual and non menstrual attacks in women with menstrually related migraine [Abstract]. Cephalalgia 2001, 21:263–264.Google Scholar
  25. 25.
    Silberstein SD, Armellino JJ, Hoffman HD, et al.: Treatment of menstruation-associated migraine with the nonprescription combination of acetaminophen, aspirin, and caffeine: results from three randomized, placebo-controlled studies. Clin Ther 1999, 21:475–491.PubMedCrossRefGoogle Scholar
  26. 26.
    Solbach MP, Waymer RS: Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol 1993, 82:769–772.PubMedGoogle Scholar
  27. 27.
    Silberstein SD, Massiou H, Le Jeunne C, et al.: Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol 2000, 96:237–242.PubMedCrossRefGoogle Scholar
  28. 28.
    Loder E, Silberstein S: Clinical Efficacy of 2.5 and 5 mg zolmitriptan in migraine associated with menses or in patients using non-progestogen contraceptives [Abstract]. Neurology 1998, 50(suppl 4):A341.Google Scholar
  29. 29.
    Massiou H, Pitei D, Poole P, et al.: Efficacy of eletriptan for the treatment of migraine in women with menstrually associated migraine, and in women on contraceptives hormone replacement therapy: meta-analysis of randomized clinical trials [Abstract]. Cephalalgia 2000, 20:435.CrossRefGoogle Scholar
  30. 30.
    Gross M, Barrie M, Bates D, et al.: The efficacy of oral sumatriptan in menstrual migraine: a prospective study [Abstract]. Cephalalgia 1995, 15(suppl 4):227.Google Scholar
  31. 31.
    Silberstein SD, Massiou H, McCarroll KA, et al.: Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache 2002, 42:917–923.PubMedCrossRefGoogle Scholar
  32. 32.
    Pinkerman B, Holroyd K: Comparison of abortive treatment for menstrually related and nonmenstrual migraines in a frequent migraine population: a preliminary report. Headache 2003, 43:512–513.Google Scholar
  33. 33.
    Visser WH, Jaspers NM, de Vriend RH, et al.: Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996, 16:264–269.PubMedCrossRefGoogle Scholar
  34. 34.
    Facchinetti F, Neri I, Martignoni E, et al.: The association of menstrual migraine with the premenstrual syndrome. Cephalalgia 1993, 13:422–425.PubMedCrossRefGoogle Scholar
  35. 35.
    Sulak PJ, Scow RD, Preece C, et al.: Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000, 95:261–266.PubMedCrossRefGoogle Scholar
  36. 36.
    Mannix LK: Management of menstrual migraine. Neurology 2003, 9:207–213. A review of abortive and preventative treatments for menstrual migraine.CrossRefGoogle Scholar
  37. 37.
    Nappi RE, Sances G, Brundu B, et al.: Neuroendocrine response to the serotonin agonist M-chlorophenylpiperazine in women with menstrual status migrainosus. Neuroendocrinology 2003, 78:52–60.PubMedCrossRefGoogle Scholar
  38. 38.
    Fioroni L, Andrea GD, Alecci M, et al.: Platelet serotonin pathway in menstrual migraine. Cephalalgia 1996, 16:427–430.PubMedCrossRefGoogle Scholar
  39. 39.
    Epstein MT, Hockaday JM, Hockaday TD: Migraine and reproductive hormones throughout the menstrual cycle. Lancet 1975, 1:543–548.PubMedCrossRefGoogle Scholar
  40. 40.
    Raskin N: Headache, edn 2. New York: Churchhill Livingstone; 1988.Google Scholar
  41. 41.
    Sances G, Martignoni E, Fioroni L, et al.: Naproxen sodium in menstrual migraine prophylaxis: a double-blind, placebocontrolled study. Headache 1990, 30:705–709.PubMedCrossRefGoogle Scholar
  42. 42.
    Szekely B, Merryman S, Croft H, et al.: Prophylactic effects of naproxen sodium on perimenstrual headache: a doubleblind, placebo-controlled study [Abstract]. Cephalalgia 1989, 9(suppl 10):452–453.Google Scholar
  43. 43.
    Gallagher RM: Menstrual migraine and intermittent ergonovine therapy. Headache 1989, 29:366–367.PubMedCrossRefGoogle Scholar
  44. 44.
    D’Alessandro R, Gamberini G, Lozito A, et al.: Menstrual migraine: intermittent prophylaxis with a timed-release pharmacological formulation of dihydroergotamine. Cephalalgia 1983, 3(suppl 1):156–158.PubMedGoogle Scholar
  45. 45.
    de Lignieres B, Vincens M, Mauvais-Jarvis P, et al.: Prevention of menstrual migraine by percutaneous oestradiol. Br Med J (Clin Res Ed) 1986, 293:1540.CrossRefGoogle Scholar
  46. 46.
    Dennerstein L, Morse C, Burrows G, et al.: Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol 1988, 2:113–120.PubMedGoogle Scholar
  47. 47.
    MacGregor A, Frith A, Ellis J, et al.: Estrogen “withdrawal:” A trigger for migraine? A double-blind, placebo-controlled study of estrogen supplements in the late luteal phase in women with migraine [Abstract]. Cephalalgia 2003, 23:684.Google Scholar
  48. 48.
    Pfaffenrath V: Efficacy and safety of percutaneous estradiol vs. placebo in menstrual migraine [Abstract]. Cephalalgia 1993, 13(suppl 13):244.Google Scholar
  49. 49.
    Smits MG, van der Meer YG, Pfeil JP, et al.: Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache 1994, 34:103–106.PubMedCrossRefGoogle Scholar
  50. 50.
    Pradalier A, Vincent D, Beaulieu P, et al.: Correlation between oestradiol plasma level and therapeutic effect on menstrual migraine. In New Advances in Headache Research, edn 4. Edited by Rose C. London: Smith-Gordon; 1994:129–132.Google Scholar
  51. 51.
    Calhoun A: A novel specific prophylaxis for the estrogen withdrawal migraine [Abstract]. Headache 2003, 43:547.Google Scholar
  52. 52.
    O’Dea JP, Davis EH: Tamoxifen in the treatment of menstrual migraine. Neurology 1990, 40:1470–1471.PubMedGoogle Scholar
  53. 53.
    Mathew P, Fung F: Recapitulation of menstrual migraine with tamoxifen. Lancet 1999, 353:467–468.PubMedCrossRefGoogle Scholar
  54. 54.
    Newman LC, Lipton RB, Lay CL, et al.: A pilot study of oral sumatriptan as intermittent prophylaxis of menstruationrelated migraine. Neurology 1998, 51:307–309.PubMedGoogle Scholar
  55. 55.
    Newman L, Mannix LK, Landy S, et al.: Naratriptan as shortterm prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 2001, 41:248–256.PubMedCrossRefGoogle Scholar
  56. 56.
    Dowson A, Brandes J, Loftus J, et al.: Naratriptan as intermittent prophylaxis for menstrually associated migraine (MAM): a review of efficacy and tolerability [Abstract]. Eur J Neurol 2003, 10(suppl 1):73.Google Scholar
  57. 57.
    Silberstein S, Elkind A, Schrieber C: Frovatriptan, a selective 5HT 1D/1B agonist, is effective for prophylaxis of menstrually associated migraine [Abstract]. Neurology 2003, 60:A94.Google Scholar
  58. 58.
    Loder E: Prophylaxis of menstrual migraine with triptans: problems and possibilities. Neurology 2002, 59:1677–1681. A review of the rational and pitfalls in the use of triptans for the shortterm prevention of menstrual migraine.PubMedGoogle Scholar
  59. 59.
    Mauskop A, Altura BT, Altura BM: Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine. Headache 2002, 42:242–248.PubMedCrossRefGoogle Scholar
  60. 60.
    Facchinetti F, Sances G, Borella P, et al.: Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991, 31:298–301.PubMedCrossRefGoogle Scholar
  61. 61.
    Sargent J, Solbach P, Damasio H, et al.: A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache 1985, 25:320–324.PubMedCrossRefGoogle Scholar
  62. 62.
    Grimes DA, Godwin AJ, Rubin A, et al.: Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstet Gynecol 1994, 83:29–34.PubMedGoogle Scholar
  63. 63.
    Ryan RE: A controlled study of the effect of oral contraceptives on migraine. Headache 1978, 17:250–251.PubMedCrossRefGoogle Scholar
  64. 64.
    Whitty CW, Hockaday JM, Whitty MM: The effect of oral contraceptives on migraine. Lancet 1966, 1:856–859.PubMedCrossRefGoogle Scholar
  65. 65.
    Cachrimanidou AC, Hellberg D, Nilsson S, et al.: Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception 1993, 48:205–216.PubMedGoogle Scholar
  66. 66.
    Martin V, Wernke S, Mandell K, et al.: Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache. Headache 2003, 43:309–321.PubMedCrossRefGoogle Scholar
  67. 67.
    Murray SC, Muse KN: Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and “add-back” therapy. Fertil Steril 1997, 67:390–393.PubMedCrossRefGoogle Scholar
  68. 68.
    Lichten EM, Bennett RS, Whitty AJ, et al.: Efficacy of danazol in the control of hormonal migraine. J Reprod Med 1991, 36:419–424.PubMedGoogle Scholar
  69. 69.
    Burke BE, Olson RD, Cusack BJ: Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomed Pharmacother 2002, 56:283–288.PubMedCrossRefGoogle Scholar
  70. 70.
    Herzog AG: Continuous bromocriptine therapy in menstrual migraine. Neurology 1997, 48:101–102.PubMedGoogle Scholar

Copyright information

© urrent Science Inc 2004

Authors and Affiliations

  • Vincent T. Martin
    • 1
  1. 1.Division of General Internal MedicineUniversity of CincinnatiCincinnatiUSA

Personalised recommendations